FEB 2015 ARTICLE LIST >>
PharmaTutor (February- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 2)
Received On: 24/11/2014; Accepted On: 03/12/2014; Published On: 01/02/2015
AUTHORS: Anuradha Sharma1*, Vaibhav Walia2, Monika Gahlawat3
1Division of Pharma. Chemistry,2 Division of Pharmacology,3 Division of Pharmaceutics,
G.V.M. College of Pharmacy,
Sonepat, Haryana, India
*anusarswat@gmail.com
ABSTRACT: Type 2 diabetes is one of the major life threatening diseases worldwide. These cases are progressing at an incremental rate every year and number of research works is going on to control the disease by targeting its enzymes or proteins. In modern drug designing, molecular docking is routinely used for understanding drug receptor interaction. In the present study molecular docking were performed on a diverse set of N-(2-benzoylphenyl)-L-tyrosine derivatives that demonstrate antidiabetic activity by stimulating peroxisome proliferator activated receptor- γ. The docking program in Glide dock justifies the correlation between the experimental values and the values derived computationally. Therefore, the dock analysis performed in Glide dock suggests the importance of evaluating the prediction accuracy of scoring functions adopted in various docking program.
How to cite this article: A Sharma, V Walia, M Gahlawat; Molecular Docking Studies of N-(2-Benzoylphenyl)-L-Tyrosine Derivatives with Anti-Diabetic Activity of Type 2 Diabetes; PharmaTutor; 2015; 3(2); 58-68
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. who.int/mediacentre/factsheets/fs312/en/.
2. LeRoith D; Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities; Am J Med.; 2002; 113: S-11S.
3. Gerich JE; The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity; Endocr Rev; 1998; 19; 491-503.
4. Gloyn A;. The search for type 2 diabetes genes; Ageing Res Rev; 2003; 2; 111-127.
5. Anjana RM., Pradeepa R., Deepa M; ICMR-INDIAB Collaborative Study Group: prevalence of diabetes and prediabetes (impaired fasting glucose or/and impaired glucose tolerance) in rural and urban India: phase 1 results of the Indian Council of Medical Research- INdiaDIABetes (INDIAB) study. Diabetologia; 2011; 54( 12): 3022-3027.
6. Tota K., Rayabarapu N., Moosa S., Talla V., Bhyravbhatla B., Rao S; InDiaMed: a comprehensive database of Indian medicinal plants for diabetes,” Bioinformation; 2013; 9(7); 378-380.
7. Lengauer T., Rarey M; Computational methods for bimolecular docking; Curr. Opin. Struct. Biol; 1996; 6(3); 402-406.
8. Kitchen DB., Decornez H., Furr JR., Bajorath J; Docking and scoring in virtual screening for drug discovery: methods and applications; Nature reviews. Drug disc; 2004; 3(11); 935-949.
9. Cobb JE., Blanchard SG., Boswell EG., Brown KK., Charifson PS., Cooper JP., Collins Jl., Dezube M., Henke BR., Hull-Ryde EA., Lake DH., Lenhard JM., Oliver W Jr., Oplinger J., Pentti M., Parks DJ., Plunket KD., Tong WQ; N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists 3 Structure Activity Relationship and Optimization of the N-Aryl Substituent; J Med Chem; 1998; 41;5055-5069.
10. Henke BR., Blanchard SG., Brackeen MF., Brown KK., Cobb JE., Collins JL., Harrington WW Jr., Hashim MA., Hull-Ryde EA., Kaldor I., Kliewer SA., Lake DH., Leesnitzer LM., Lehmann JM., Lenhard JM., Orband-Miller LA., Miller JF., Mook RA Jr., Noble SA., Oliver W Jr., Parks DJ., Plunket KD., Szewczyk JR., Willson TM; N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists.1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents; J Med Chem 1998; 41; 5020-5036.
11. Maestro, version 9.1; LigPrep, version 2.4; Glide version 5.6; Schrodinger, New York, NY; 2009.
.png)
